antimony/nausea

Lyen an sove nan clipboard la

Chwazi kalite sòt

12 rezilta yo

Toxicity of antimony and its compounds.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Experimental and clinical experience with compounds containing antimony have shown that the trivalent compounds are generally more toxic than the pentavalent ones. APT can cause severe pain and tissue necrosis and is therefore not given by intramuscular or subcutaneous injection. APT has the actions

THE MECHANISM OF THE VOMITING INDUCED BY ANTIMONY AND POTASSIUM TARTRATE (TARTAR EMETIC).

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

1. It has been shown that tartar emetic acts on the stomach to induce emesis after its oral administration, that only traces are present in the vomitus following its intravenous injection (Kleimann and Simonowitsch), and that it does not induce emesis when it is applied directly to the vomiting

The effects of drugs on Onchocerca volvulus. 2. The antimonial preparations TWSb and MSbE.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Antimonial preparations (Pentostam, Neostibosan, stibophen, and tartar emetic) have occasionally been used in the treatment of onchocerciasis without very promising results. The advent of the preparations TWSb (stibocaptate) and MSbE (Friedheim) of allegedly reduced toxicity made it desirable to

[Oral miltefosine to treat leishmaniasis].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Reduced efficacy, difficulties of administration and increasing frequency and severity of adverse events of pentavalent antimony have stimulated the quest for new anti-leishmanial drugs. Several clinical studies in Latin America testing injectable, oral and topical anti-leishmanial drugs have

A case of visceral leishmaniasis in Oltenia region (Romania).

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Visceral leishmaniasis is produced by a protozoan parasite that belongs to the genus Leishmania. Transmission is made through sting, the vector being represented by a species of the genus Phlebotomus. The first case of visceral leishmaniasis in Romania was reported by Manicatide (1912). In 1934, it

[Hematologic characteristics of leishmaniasis].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Leishmaniasis is a chronic infectious disease from the group of anthropozoonoses. It is caused by protozoa in the genus leishmania flagellate. There are five major foci of this disease in the world: India, Mediterranean countries, East Africa, South China and South America. Endemic

Treatment of New World cutaneous leishmaniasis with miltefosine.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Miltefosine (2.5 mg/kg/day for 28 days) was investigated for treatment of New World cutaneous leishmaniasis in Colombia and Guatemala. The data from a controlled study was remarkably similar to the data of a prior uncontrolled pilot study. In the controlled study, the per-protocol 6-month cure rate

PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

American tegumentary leishmaniasis is an infectious disease caused by a protozoan of the genus Leishmania. Pentavalent antimonials are the first choice drugs for cutaneous leishmaniasis (CL), although doses are controversial. In a clinical trial for CL we investigated the occurrence of pancreatic

Pentamidine: a review.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Pentamidine, recently released for clinical use, is effective in therapy for the hemolymphatic stage of Gambian trypanosomiasis, antimony-resistant leishmaniasis, and Pneumocystis carinii pneumonia. The mechanism of action is unclear and may differ for different organisms. Trypanosomes actively

Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Cutaneous leishmaniasis (CL) is treated with parenteral drugs for decades with decreasing rate cures. Miltefosine is an oral medication with anti-leishmania activity and may increase the cure rates and improve compliance. RESULTS This study is a randomized, open-label, controlled clinical

Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Cutaneous leishmaniasis is an endemic disease in Surinam. The disease was treated until the early 1970s with pentavalent antimony. Pentamidine mesylate was introduced by Niemel in 1973 for the treatment of cutaneous leishmaniasis in Surinam. METHODS In this retrospective study, we

Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Miltefosine has been used in the treatment of several new world cutaneous leishmaniasis (CL) species with variable efficacy. Our study is the first evidence on its clinical efficacy in Leishmania (Viannia) guyanensis. In this phase II/III randomized clinical trial, 90 CL patients were randomly

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye